BBOT BridgeBio Oncology Therapeutics, Inc.
Mergers ·
BridgeBio Oncology Therapeutics, the former Helix Acquisition Corp. II, closed its merger on August 11, 2025 and reports gross proceeds of approximately $381.8 million. BBOT's unaudited statements show a net loss of $50,490 thousand and $42,892 thousand used in operations for the first half of 2025.
Helix says about $120 million remains in trust after redemptions, and that a $261 million private placement led by Cormorant Asset Management would bring the merger with BBOT to about $382 million gross.
The shell company says the registration statement for its merger with BBOT is effective and set a shareholder meeting for August 4, 2025, but the release gives no deal value or minimum cash figure.
The blank-check company's annual report says it must liquidate if it does not close its deal with BridgeBio Oncology by February 14, 2026, and that doubt over its ability to continue is substantial.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $121.2 million | $73.1 million |
| Net income (loss) | -$134.0 million | -$74.3 million |
| Cash from operations | -$113.9 million | -$55.0 million |
| Cash and equivalents | $373.7 million | $30.9 million |
| Short-term investments | $51.8 million | $124.8 million |
Our latest story on this, dated Aug 6, 2025: "Helix Acquisition Corp. II (now BridgeBio Oncology) keeps $120 million in trust". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 13, 2025: "Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) completes business combination". The story links the filing or release it is based on. Read the story.
BridgeBio Oncology Therapeutics, Inc. trades under the ticker BBOT on NASDAQ.
BridgeBio Oncology Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:BBOT; BMV:BBOT.
The SEC Central Index Key (CIK) for BridgeBio Oncology Therapeutics, Inc. is 1869105. Its filings are on SEC EDGAR.
80,174,267 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11.
Our directory records BridgeBio Oncology Therapeutics, Inc. under United States.
Our directory classifies BridgeBio Oncology Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for BridgeBio Oncology Therapeutics, Inc. is US1079241022.
aibio.space lists BridgeBio Oncology Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
BridgeBio Oncology Therapeutics, Inc. reported a net loss of $134.0 million for the fiscal year ended Dec 31, 2025, and used $113.9 million of cash in operations, per its annual report to the SEC.
$121.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$225.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on BridgeBio Oncology Therapeutics, dated Aug 13, 2025: "Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) completes business combination". BridgeBio Oncology Therapeutics, the former Helix Acquisition Corp. II, closed its merger on August 11, 2025 and reports gross proceeds of approximately $381.8 million. BBOT's unaudited statements show a net loss of $50,490 thousand and $42,892 thousand used in operations for the first half of 2025. Source.
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,4.01,5.01,5.02,5.03,5.05,5.06,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio